The realm of interchangeable biologics is a complex and rapidly evolving field with far-reaching implications for pharmacists and the broader healthcare landscape. As biologics and biosimilars continue to revolutionize modern medicine, it is crucial for pharmacists to comprehensively understand the scientific and practical considerations surrounding these intricate therapeutic agents (Stevenson et al., 2023). The multidisciplinary analysis aims to equip pharmacists with the knowledge and insights to navigate the evolving landscape of interchangeable biologics confidently and effectively.
Pharmacists play a pivotal role in medication management and substitution decisions, making it essential for them to grasp the nuances involved in determining interchangeability (Hobbs & Crawford, 2019). As medication experts and patient advocates, pharmacists are responsible for ensuring the safe and appropriate use of biologics and biosimilars. They also must educate patients while addressing concerns and fostering adherence to prescribed therapies (Frapaise, 2019). The availability of interchangeable biologics can improve patient access and reduce healthcare costs. The complexities of establishing interchangeability and the potential for variations in manufacturing processes demand vigilance and careful consideration (Afzali et al., 2021). Interchangeable biologics present unique challenges and opportunities for pharmacists.
Defining Interchangeability
Scientific Perspective
From a scientific standpoint, interchangeability refers to the ability of a biosimilar product to be substituted for its reference biologic without compromising safety, purity or potency (McCamish et al., 2015). Its determination relies on rigorous analytical and functional characterization demonstrating highly similar structural and pharmacokinetic properties between the biosimilar and the reference product (Ratih et al., 2021). Advanced analytical techniques such as mass spectrometry, nuclear magnetic resonance (NMR) and spectroscopy play crucial roles in elucidating the intricate molecular landscapes and establishing their scientific equivalence (Ebbers, 2020). NMR spectroscopy is another invaluable tool in defining three-dimensional structures and conformational features of proteins and biomolecules. By revealing atomic-level details, NMR assists in identifying and comparing the higher-order structures of biosimilars and reference biologics, further solidifying the foundation for interchangeability assessments.
Legal Perspective
From a legal perspective, interchangeability is a specific designation granted by regulatory authorities, such as the U.S. Food and Drug Administration, after meeting stringent criteria outlined in their respective guidelines and regulations (FDA, n.d.-a). Biosimilar manufacturers must provide robust scientific evidence including comprehensive analytical data, pharmacokinetic studies and clinical trial results ((Kurki et al., 2021). The data should demonstrate the high similarity between the proposed interchangeable biosimilar and its reference product (O’Callaghan et al., 2019). Regulatory authorities mandate detailed studies on the potential for immune system interactions and the formation of anti-drug antibodies, as these factors can significantly influence the safety and efficacy of interchangeable biologics.
Clinical Perspective
From a clinical standpoint, interchangeability implies that a biosimilar can be substituted for its reference biologic at the pharmacy level without compromising patient outcomes or requiring additional monitoring or intervention (Alvarez et al., 2020). Robust clinical trials and real-world evidence are essential to establish the clinical equivalence of interchangeable biologics, ensuring that factors such as efficacy, safety, immunogenicity, and patient-reported outcomes are comparable to those of the reference product (Cramer, 2021; de Mora et al., 2019). In addition to clinical trials, real-world evidence (RWE) generated from observational studies and post-marketing surveillance data offers invaluable insights into the practical implications of interchangeable biologics.
Pharmacovigilance
Pharmacovigilance, or the continuous monitoring and evaluation of drug safety, plays a crucial role in interchangeable biologics (Panozzo et al., 2020). Given the complexity of these therapeutic agents and the potential for variations in manufacturing processes, robust post-marketing surveillance systems are essential to detect and investigate any unexpected adverse events, immunogenicity issues, or changes in efficacy.
Pharmacovigilance systems should be designed to capture and analyze data from various sources, including spontaneous reporting systems, electronic health records, patient registries, and observational studies, enabling the detection of rare or long-term adverse events (Park et al., 2022). Pharmacists are well-positioned to contribute significantly to pharmacovigilance efforts through their frontline interactions with patients and their expertise in medication management (Joshi et al., 2023). By actively monitoring patient outcomes, reporting adverse events, and providing feedback to regulatory authorities and manufacturers, pharmacists can play a vital role in identifying and addressing safety concerns related to interchangeable biologics.
Patient Education and Adherence
Pharmacists are critical in educating patients about interchangeable biologics and fostering adherence to prescribed therapies (FDA, n.d.-b). As medication experts and patient advocates, pharmacists are often the primary source of information and counseling for patients with concerns or questions regarding these complex therapeutic agents.
Patient education addresses potential misconceptions, alleviates concerns, and promotes a better understanding of the scientific principles and regulatory processes underlying interchangeable biologics (Barbier et al., 2022). Pharmacists can leverage their knowledge and communication skills to explain the rigorous analytical and clinical evaluations that biosimilars undergo to obtain the interchangeable designation, highlighting the similarities in safety, efficacy, and quality compared to their reference counterparts.
Adherence to prescribed biologic therapies is another area where pharmacists can have a significant impact (Cho & Jun, 2021). By building trust and establishing open lines of communication with patients, pharmacists can identify and address potential barriers to adherence, such as cost concerns, side effect management, or logistical challenges. Through collaborative efforts with other healthcare professionals and leveraging adherence-enhancing strategies, pharmacists can help optimize treatment outcomes and ensure patients receive the full benefits of their prescribed interchangeable biologic therapies.
Pharmacoeconomic Considerations
The introduction of interchangeable biologics also has significant pharmacoeconomic implications that pharmacists should consider (Nair, 2020). While biosimilars generally offer cost-saving opportunities compared to their reference counterparts, a comprehensive evaluation of the financial impact on patients, payers, and the healthcare system is necessary.
Pharmacists can contribute to pharmacoeconomic analyses by providing insights into medication adherence, dosing regimens, and potential adverse event management costs (Rathore et al., 2022). By collaborating with other stakeholders, including payers, policymakers, and healthcare administrators, pharmacists can help develop cost-effective strategies for adopting and appropriately utilizing interchangeable biologics.
Economic modeling and cost-effectiveness studies can inform decision-making processes, ensuring that healthcare resources are allocated efficiently while maintaining high-quality patient care (Sacks et al., 2021). With their deep understanding of medication costs, reimbursement policies, and patient access considerations, pharmacists can play a crucial role in interpreting and communicating these pharmacoeconomic analyses to various stakeholders.
To enhance the understanding and communication of critical concepts related to interchangeable biologics, visual aids and illustrations can be incorporated into educational materials and resources (FDA, 2023). These visual elements can help simplify complex scientific and regulatory concepts, making them more accessible to a broader audience, including pharmacists, healthcare professionals, and patients.
Conclusion
The analysis highlights the multifaceted nature of interchangeable biologics and pharmacists’ pivotal role in ensuring their safe, effective, and appropriate utilization. By bridging knowledge gaps, providing insights into emerging perspectives, and incorporating visual aids and illustrations, pharmacists can navigate this complex landscape confidently. As integral healthcare team members, pharmacists contribute to improved patient outcomes and the advancement of modern pharmacological practices through their expertise in medication management, patient education, pharmacovigilance, and pharmacoeconomic considerations.
References
Afzali, A., Furtner, D., Melsheimer, R., & Molloy, P. J. (2021). The automatic substitution of biosimilars: definitions of interchangeability are not interchangeable. Advances in Therapy, 38, 2077-2093.
Alvarez, D. F., Wolbink, G., Cronenberger, C., Orazem, J., & Kay, J. (2020). Interchangeability of biosimilars: What level of clinical evidence is needed to support the interchangeability designation in the United States?. BioDrugs, 34, 723-732.
Barbier, L., Vandenplas, Y., Barcina Lacosta, T., & Vulto, A. (2022). Biosimilar Interchangeability: Regulatory & Practical Considerations.
Cho, S. K., & Jun, H. (2021). Substitution of generic drugs and biosimilars. JAMA Internal Medicine, 181(4), 567-568.
Cramer, G. (2021, January 19). The Journey from Biologic to Biosimilar—A Clinical Perspective. ACRP. https://acrpnet.org/2021/01/the-journey-from-biologic-to-biosimilar-a-clinical-perspective/
de Mora, F., Balsa, A., Cornide‐Santos, M., Carrascosa, J. M., Marsal, S., P. Gisbert, J., … & Martínez, R. (2019). Biosimilar and interchangeable: Inseparable scientific concepts?. British Journal of Clinical Pharmacology, 85(11), 2460-2463.
Ebbers, H. C. (2020). Biosimilarity and Interchangeability of Biologic Drugs‐General Principles, Biophysical Tests, and Clinical Requirements to Demonstrate Biosimilarity. Biologics, Biosimilars, and Biobetters: An Introduction for Pharmacists, Physicians, and Other Health Practitioners, 109-124.
Esco Micro Pte Ltd. (n.d.). Large Molecule. Www.escopharma.com. https://www.escopharma.com/solutions/by-application-large-molecule
FDA, U. S. (n.d.). Biosimilars: What Patients with Diabetes Need to Know | FDA. Www.fda.gov. Retrieved January 18, 2024, from https://www.fda.gov/media/166335/
FDA, U. S. (n.d.). Prescribing Interchangeable Products Can interchangpharmacists substitute eable products be substitnce products by pharmad January 18, 2024, from https://www.fda.gov/files/drugs/published/Prescribing-Interchangeable-Products.pdf
Frapaise, F. X. (2019). Biosimilars: patient perspectives, challenges and emerging solutions: current opinions. J Drug Res Dev, 5(1), 2470-1009.
Hobbs, A. L., & Crawford, J. P. (2019). Biosimilars and implications for pharmacy practice: Ready or not, here they come! Pharmacy Practice (Granada), 17(3).
Joshi, S. R., Mittra, S., Raj, P., Suvarna, V. R., & Athalye, S. N. (2023). Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective. Expert Opinion on Biological Therapy, 23(8), 693-704.
Kurki, P., Barry, S., Bourges, I., Tsantili, P., & Wolff-Holz, E. (2021). Safety, immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: a regulatory perspective. Drugs, 81, 1881-1896.
McCamish, M., Pakulski, J., Sattler, C., & Woollett, G. (2015). Toward interchangeable biologics. Clinical Pharmacology & Therapeutics, 97(3), 215–217. https://doi.org/10.1002/cpt.39
Murdock, J. (2023, March 2). A List of 7 Biosimilars FDA Approved in 2022. GoodRx; GoodRx. https://www.goodrx.com/drugs/biologics/fda-approved-biosimilar-drugs-list
Nair, S. (2020). Facilitators and Barriers to Biosimilar Adoption: a Systematic Review of the Global Stakeholder Perspective.
O’Callaghan, J., Barry, S. P., Bermingham, M., Morris, J. M., & Griffin, B. T. (2019). Regulation of biosimilar medicines and current perspectives on interchangeability and policy. European journal of clinical pharmacology, 75, 1-11.
Office of the Commissioner. (2021). Biosimilar and Interchangeable Biologics: More Treatment Choices. FDA. https://www.fda.gov/consumers/consumer-updates/biosimilar-and-interchangeable-biologics-more-treatment-choices
Panozzo, C. A., Huang, K., & Lu, C. Y. (2020). Pharmacovigilance of Innovator Biologics and Biosimilars. Biologics, Biosimilars, and Biobetters: An Introduction for Pharmacists, Physicians, and Other Health Practitioners, 177-194.
Park, J. P., Jung, B., Park, H. K., Shin, D., Jung, J. A., Ghil, J., … & Woollett, G. R. (2022). Interchangeability for biologics is a legal distinction in the USA, not a clinical one. BioDrugs, 36(4), 431-436.
Rathore, A. S., Stevenson, J. G., Chhabra, H., & Maharana, C. (2022). The global landscape on interchangeability of biosimilars. Expert Opinion on Biological Therapy, 22(2), 133-148.
Ratih, R., Asmari, M., Abdel-Megied, A. M., Elbarbry, F., & El Deeb, S. (2021). Biosimilars: Review of regulatory, manufacturing, analytical aspects and beyond. Microchemical Journal, 165, 106143.
Research, C. for D. E. and. (2023). Updated FDA Labeling Recommendations for Biosimilar and Interchangeable Biosimilar Products. FDA. https://www.fda.gov/drugs/our-perspective/updated-fda-labeling-recommendations-biosimilar-and-interchangeable-biosimilar-products
Sacks, C. A., Van de Wiele, V. L., Fulchino, L. A., Patel, L., Kesselheim, A. S., & Sarpatwari, A. (2021). Assessment of variation in state regulation of generic drug and interchangeable biologic substitutions. JAMA internal medicine, 181(1), 16-22.
Stevenson, J. G., McCabe, D., McGrath, M., & McBride, A. (2023). Pharmacist biosimilar survey reveals knowledge gaps. Journal of the American Pharmacists Association, 63(2), 529-537.